ISRCTN09311427已完成2 期
High dose therapy of relapsed or refractory aggressive non-Hodgkin lymphoma: a phase II study
Eastern German Study Group for Haematology and Oncology (OSHO) (Germany)0 个研究点目标入组 100 人开始时间: 2012年3月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Refractory or relapsed aggressive Non-Hodgkin lymphoma
- •2. Age 18 - 65 years
- •?3. Performance-Status (Karnofsky more than 60 %)
- •4. Absolute neutrophil count (ANC) >1.5/µl
- •5. Platelets (PLT) >100/µl
- •6. Creatinin clearance > 1 ml/sec
- •7. Liver function test > 1.5 fold of upper normal level (UNL)
- •8. Bilirubin < 22 µmol/l
- •9. Informed consent
- •10. No participation in another trial
排除标准
- •1. Second malignoma in the history other than basalioma
- •2. Central nervous system (CNS) lymphoma
- •3. Respiratory failure
- •4. Heart failure [New York Heart Association (NYHA) stage 3-4, ejection fraction < 30 %]
- •5. Severe neurological / psychiatric disease?
- •6. Pregnancy, ineffective contraception
- •7. Preceding kidney transplantation
- •8. Positive Human immunodeficiency virus (HIV) test
- •9. Active viral hepatitis
- •10. Bacterial infection
研究者
相似试验
已完成
2 期
2nd Nordic Mantle-Cell Lymphoma protocolMantle cell lymphomaCancerLymphomaISRCTN87866680Individual sponsor (Denmark)50
进行中（未招募）
不适用
Stereotactic body radiotherapy for the treatment of OPDung cancerCancerLung cancerISRCTN53398136Institute of Cancer Research110
招募中
2 期
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retroviral vector – A unicenter Phase I/II clinical trial [HD-CAR-1]2024-516832-82-00Universitaetsklinikum Heidelberg AöR63
已完成
不适用
Therapy of frequent relapsing, steroid-sensitive nephrotic syndrome in childhood: efficacy of mycophenolate mofetil versus cyclosporin AISRCTN61976169Hoffmann-La Roche AG (Germany)55
进行中（未招募）
1 期
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 19.1 Level: LLT Classification code 10063625 Term: Acute lymphoblastic leukemia recurrent System Organ Class: 100000004864MedDRA version: 19.1 Level: LLT Classification code 10063621 Term: Acute lymphoblastic leukaemia recurrent System Organ Class: 100000004864EUCTR2016-001991-31-ESovartis Farmacéutica, S.A.55